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Aim ESC guidelines recommend low molecular weight heparin (LMWH) and fondaparinux (fonda) over unfractionated heparin (UFH) for initial 
treatment of acute pulmonary embolism (PE), except in patients (pts) at high bleeding risk or with severe renal dysfunction. No trial has assessed 
the comparative efficacy of enoxaparin (enox) and fonda in this setting.
Methods Prospective, multicenter registry of confirmed PE pts. Pts with proven recent PE (symptom onset <15 days) and treated with approved 
regimens of enox or fonda were included. Pts with high risk PE, and those with recent (<14 days) or active bleeding, surgery <3 days, stroke <10 
days, or renal failure were excluded. To adjust for potential bias, we calculated a propensity score by logistic regression, corresponding to the 
predicted probability that patients were treated by enox as opposed to fonda. We used a combined in-hospital endpoint defined as death, recurrent 
PE, or major bleeding. Secondary endpoints were residual pulmonary vascular obstruction (RPVO) as assessed by perfusion lung scan at discharge 
and 6 months, and 6 month mortality.
Results  Among 501 pts included from 2006-2010, 229(46%) received enox and 272(54%) received fonda. Baseline characteristics were similar 
between groups. Five(2.2%) enox pts had recurrent PE vs 5(1.8%) in the fonda group (p=0.96). Thirteen(5.7%) enox pts and 9 (3.3%) fonda pts 
had major bleeding (p=0.19); in-hospital mortality was 3.5% and 1.1% respectively (p=0.07). In-hospital, 19(8.3%) enox pts reached at least one 
clinical endpoint vs 12(4.4%) fonda pts (p=0.07). After adjusting on propensity score, there was no significant difference between groups in terms of 
death, recurrent PE, major bleeding or combined endpoint (enox vs fonda, OR=1.45 [0.67-3.14]). RPVO at discharge was 28.4±14.6% vs 27.2±13.9, 
enox vs fonda, p=0.57. There was no difference in RPVO at 6 months . Six-month mortality was 8.5% vs 9.3%, enox vs fonda, p=0.76.
Conclusion Our data suggest that enox and fonda can be used interchangeably, as they have comparable efficacy and safety profiles in non-high 
risk acute PE pts. Neither molecule appears to induce an excess bleeding risk as compared to the other, although this remains to be confirmed.
